Готові списки джерел за темами / Human Liver Stem Cells

Добірка наукової літератури з теми "Human Liver Stem Cells"

Автор: Grafiati
Опубліковано: 14 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Human Liver Stem Cells".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Human Liver Stem Cells"

1

Thomas, David Brynmor. "The infusion of human fetal liver cells." Stem Cells 11, S1 (May 1993): 66–71. http://dx.doi.org/10.1002/stem.5530110614.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Jauregui, R. G., N. Fekete-Drimusz, C. Lipps, D. Wirth, M. P. Manns, F. W. R. Vondran, and M. Bock. "Mouse Liver Repopulation with Human Liver Stem Cells." Journal of Hepatology 64, no. 2 (2016): S154—S155. http://dx.doi.org/10.1016/s0168-8278(16)01655-x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Schmelzer, Eva, Lili Zhang, Andrew Bruce, Eliane Wauthier, John Ludlow, Hsin-lei Yao, Nicholas Moss, et al. "Human hepatic stem cells from fetal and postnatal donors." Journal of Experimental Medicine 204, no. 8 (July 30, 2007): 1973–87. http://dx.doi.org/10.1084/jem.20061603.

Повний текст джерела
Анотація:
Human hepatic stem cells (hHpSCs), which are pluripotent precursors of hepatoblasts and thence of hepatocytic and biliary epithelia, are located in ductal plates in fetal livers and in Canals of Hering in adult livers. They can be isolated by immunoselection for epithelial cell adhesion molecule–positive (EpCAM+) cells, and they constitute ∼0.5–2.5% of liver parenchyma of all donor ages. The self-renewal capacity of hHpSCs is indicated by phenotypic stability after expansion for >150 population doublings in a serum-free, defined medium and with a doubling time of ∼36 h. Survival and proliferation of hHpSCs require paracrine signaling by hepatic stellate cells and/or angioblasts that coisolate with them. The hHpSCs are ∼9 μm in diameter, express cytokeratins 8, 18, and 19, CD133/1, telomerase, CD44H, claudin 3, and albumin (weakly). They are negative for α-fetoprotein (AFP), intercellular adhesion molecule (ICAM) 1, and for markers of adult liver cells (cytochrome P450s), hemopoietic cells (CD45), and mesenchymal cells (vascular endothelial growth factor receptor and desmin). If transferred to STO feeders, hHpSCs give rise to hepatoblasts, which are recognizable by cordlike colony morphology and up-regulation of AFP, P4503A7, and ICAM1. Transplantation of freshly isolated EpCAM+ cells or of hHpSCs expanded in culture into NOD/SCID mice results in mature liver tissue expressing human-specific proteins. The hHpSCs are candidates for liver cell therapies.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Shafritz, David A., Mo R. Ebrahimkhani, and Michael Oertel. "Therapeutic Cell Repopulation of the Liver: From Fetal Rat Cells to Synthetic Human Tissues." Cells 12, no. 4 (February 6, 2023): 529. http://dx.doi.org/10.3390/cells12040529.

Повний текст джерела
Анотація:
Progenitor cells isolated from the fetal liver can provide a unique cell source to generate new healthy tissue mass. Almost 20 years ago, it was demonstrated that rat fetal liver cells repopulate the normal host liver environment via a mechanism akin to cell competition. Activin A, which is produced by hepatocytes, was identified as an important player during cell competition. Because of reduced activin receptor expression, highly proliferative fetal liver stem/progenitor cells are resistant to activin A and therefore exhibit a growth advantage compared to hepatocytes. As a result, transplanted fetal liver cells are capable of repopulating normal livers. Important for cell-based therapies, hepatic stem/progenitor cells containing repopulation potential can be separated from fetal hematopoietic cells using the cell surface marker δ-like 1 (Dlk-1). In livers with advanced fibrosis, fetal epithelial stem/progenitor cells differentiate into functional hepatic cells and out-compete injured endogenous hepatocytes, which cause anti-fibrotic effects. Although fetal liver cells efficiently repopulate the liver, they will likely not be used for human cell transplantation. Thus, utilizing the underlying mechanism of repopulation and developed methods to produce similar growth-advantaged cells in vitro, such as human induced pluripotent stem cells (iPSCs). This approach has great translational potential for developing novel cell-based therapies in patients with liver disease. The present review gives a brief overview of the classic cell transplantation models and various cell sources studied as donor cell candidates. The advantages of fetal liver-derived stem/progenitor cells are discussed, as well as the mechanism of liver repopulation. Moreover, this article reviews the potential of in vitro developed synthetic human fetal livers from iPSCs and their therapeutic benefits.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

RUCK, P., J‐C XIAO, T. PIETSCH, and E. KAISERLING. "Hepatic stem cells in the human liver." Histopathology 29, no. 6 (December 1996): 590–91. http://dx.doi.org/10.1046/j.1365-2559.1996.d01-547.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

ROSKAMS, T., R. DE VOS, and V. DESMET. "Hepatic stem cells in the human liver." Histopathology 29, no. 6 (December 1996): 591–92. http://dx.doi.org/10.1046/j.1365-2559.1996.d01-548.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Zhou, Ping, Ryan Lahey, Daniel Cortes, Yetunde Olusanya, Sarah Hohm, Ha Tran, David Hess, and Jan A. Nolta. "Hepatocyte-Like Cells Can Be Derived from Human Umbilical Cord Blood and Embryonic Stem Cells: Tested in a Novel Mouse Model." Blood 112, no. 11 (November 16, 2008): 3490. http://dx.doi.org/10.1182/blood.v112.11.3490.3490.

Повний текст джерела
Анотація:
Abstract Liver transplantation remains the only therapeutic option for many acute and chronic end-stage liver diseases. However, this approach is limited by a serious shortage of donor organs required for transplantation. Hepatocytes have been reported to be generated from cells not originated from liver, such as hematopoietic stem cells, mesenchymal stem cells and most recently embryonic stem cells. However, the frequency of these stem cell-derived hepatocytes is very low in most studies. Therefore, the significance of stem cell contribution to the repair of liver damage is still controversial. To further explore this potential, we used the beta-glucuronidase (GUSB)-null NOD/SCID/MPSVII mouse model for better identification of engrafted human cells. Enriched cord blood primitive cells (lineage depleted cells with high aldehyde dehydrogenase activity, ALDHhiLin−) were transplanted into irradiated NOD/SCID/MPSVII mice. One month after transplantation, carbon tetrachloride (CCl4) was administrated into the mice twice a week for 4 weeks to induce liver damage. In this model, ALDHhiLin− cells efficiently engrafted in the recipient mouse livers as demonstrated by GUSB positive immunohistological staining and the presence of human Alu DNA using PCR. The percentage of human cells in these livers ranged between 3% and 14.2% using quantitative real-time PCR. These engrafted cells improved recovery of the mice from toxic insult, and significantly increased the numbers of surviving mice. Furthermore, human liver-specific a-1-antitrypsin mRNA and albumin protein were expressed in the recipient livers. Interestingly, human vs. murine centromeric fluorescent in situ hybridization analysis on the liver sections demonstrated that most human cells were not fused to mouse cells. However, mouse nuclei were detected in the majority of the albumin-expressing cells, suggesting that fusion had occurred and was responsible for the appearance of donor derived hepatocyte-like cells. With the goal of achieving higher levels of liver reconstitution than had been possible using the adult stem cells, we began studying engraftment of human embryonic stem cells (hESC), which theoretically have the potential to regenerate any tissue. The H1 cell line was cultured on mouse embryonic fibroblasts then allowed to form embryoid bodies (EBs) in suspension culture for 7 days with or without further expansion and differentiation in attached culture for another month. EBs were dissociated into a single cell suspension and transplanted into NOD/SCID/MPSVII mice or NOD/SCID/IL2Rγ−/− mice via the tail vein after 300 RADs sublethal radiation with or without CCl4 administration. Two months post-transplantation, the human EB-derived cells were found to be well engrafted in the NOD/SCID/MPSVII mouse livers, spleens and kidneys, using the clear-cut enzymatic identification method for cells expressing normal levels of beta-glucuronidase in the mice, which are null for the enzyme. Human DNA was also detected in the recipient mouse liver. Most interestingly, human albumin-expressing cells were also found in the livers of engrafted mice. Our data indicate that the progeny of cord blood stem cells can significantly enhance survival of mice with severe liver damage, and that fusion can occur between transplanted and recipient cells. This could be a normal mechanism of liver repair, since hepatocytes exist normally as multinucleate cells. We also demonstrate that the progeny of hESC can be effectively dissociated and transplanted intravenously, then home to the liver and differentiate to the hepatocyte lineage in an immune deficient mouse model of liver damage.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Najimi, Mustapha, Dung Ngoc Khuu, Philippe Antoine Lysy, Nawal Jazouli, Jorge Abarca, Christine Sempoux, and Etienne Marc Sokal. "Adult-Derived Human Liver Mesenchymal-Like Cells as a Potential Progenitor Reservoir of Hepatocytes?" Cell Transplantation 16, no. 7 (August 2007): 717–28. http://dx.doi.org/10.3727/000000007783465154.

Повний текст джерела
Анотація:
It is currently accepted that adult tissues may develop and maintain their own stem cell pools. Because of their higher safety profile, adult stem cells may represent an ideal candidate cell source to be used for liver cell therapies. We therefore evaluated the differentiation potential of mesenchymal-like cells isolated from adult human livers. Mesenchymal-like cells were isolated from enzymatically digested adult human liver and expanded in vitro. Cell characterization was performed using flow cytometry, RT-PCR, and immunofluorescence, whereas the differentiation potential was evaluated both in vitro after incubation with specific media and in vivo after intrasplenic transplantation of uPA+/+-SCID and SCID mice. Adult-derived human liver mesenchymal-like cells expressed both hepatic and mesenchymal markers among which albumin, CYP3A4, vimentin, and α-smooth muscle actin. In vitro differentiation studies demonstrated that these mesenchymal-like cells are preferentially determined to differentiate into hepatocyte-like cells. Ten weeks following intrasplenic transplantation into uPA+/+-SCID mice, recipient livers showed the presence of human hepatocytic cell nodules positive for human albumin, prealbumin, and α-fetoprotein. In SCID transplanted liver mice, human hepatocyte-like cells were mostly found near vascular structures 56 days posttransplantation. In conclusion, the ability of isolated adult-derived liver mesenchymal stem-like cells to proliferate and differentiate into hepatocyte-like cells both in vitro and in vivo leads to propose them as an attractive expandable cell source for stem cell therapy in human liver diseases.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Irudayaswamy, Antony, Mark Muthiah, Lei Zhou, Hau Hung, Nur Halisah Bte Jumat, Jamil Haque, Narcissus Teoh, et al. "Long-Term Fate of Human Fetal Liver Progenitor Cells Transplanted in Injured Mouse Livers." STEM CELLS 36, no. 1 (October 13, 2017): 103–13. http://dx.doi.org/10.1002/stem.2710.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Navarro-Tableros, Victor, Maria Beatriz Herrera Sanchez, Federico Figliolini, Renato Romagnoli, Ciro Tetta, and Giovanni Camussi. "Recellularization of Rat Liver Scaffolds by Human Liver Stem Cells." Tissue Engineering Part A 21, no. 11-12 (June 2015): 1929–39. http://dx.doi.org/10.1089/ten.tea.2014.0573.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Human Liver Stem Cells"

1

Chen, Shi. "Cryopreservation of human embryonic stem cells and hepatocytes." Thesis, University of Oxford, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.711665.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Jennings, Adam Edward. "Control of growth and differentiation of human liver stem cells." Thesis, University of Birmingham, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.403607.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

LAI, FEDERICA. "Immunohystochemical markers of stem/progenitor cells in the fetal human liver." Doctoral thesis, Università degli Studi di Cagliari, 2019. http://hdl.handle.net/11584/260751.

Повний текст джерела
Анотація:
The documentation and the characterization of human stem/progenitor cells of the liver is interesting subject of the current scientific literature. Stem/progenitor cells are a heterogenus population characterized by a range of morphological and immunohistochemical features from bile duct cells to hepatocytes. They are typically characterized by the self-renewal ability able to differentiate into diverse lineage after injury or damage.. This study evaluated the immunohistochemical expression of different type of cytokeratins (CK7, CK14 and CK19) at different gestational ages in order to identify stem/progenitor in fetal human liver. Objectives: The aim of this study was to identify the stem/progenitor cell markers, by immunohistochemistry, in order to highlight the immunoreactivity of CK7, CK14 and CK19 in human liver progenitor cells at different gestational ages. Material and Methods: Liver samples were obtained from 14 fetal liver from 7 to 38 weeks of gestation. Liver samples were formalin-fixed routinely processed and stained with with H&E for histology. Section were also immunostained with the following antibodies: anti-CK7, anti-CK14 and anti-CK19. Results: Cytokeratin 7 (CK7): From 7 to 12 weeks of gestation, the positivity for CK7 is evident in the cytoplasm of progenitor cells of hepatocytes. From 15 weeks to 19 weeks, its immunoreactivity is absent. At about 27 weeks up to 38 weeks, we have a moderate positivity than before. The bile ducts in the first 7 weeks of gestation are absent. From 15 weeks onwards, we have a strong positivity of CK7 in ductal cells, remaining until late gestational age. The positivity of CK7 in the bile ducts is cytoplasmic and perinuclear. Cytokeratin 14 (CK14): From 7 weeks to 12 weeks, a cytoplasmic positivity, mainly perinuclear, is present in the cytoplasm of progenitor cells. From 15 weeks to 19 weeks, no immunoreactivity was found in hepatoblasts. From 27 weeks up to 38 weeks, there is a positive recovery. On the other hand, there is no positive effect during the development of the ductal system. Cytokeratin 19 (CK19): From 7 to 12 weeks of gestation, we have an intense cytoplasmic positivity homogeneously spread at the level of progenitor cells. At 15 weeks it is more light and focal and then negativize and start again from 27 weeks. Like CK7, also the CK19 is intensely expressed in the bile ducts from 15 weeks and then maintained until the 38th gestational age studied. Conclusion: Immunohistochemistry with monoclonal anti-cytokeratin antibodies has revelated previously the presence of cytokeratins in embryonic and early fetal hapatocytes. With the differentiation of bile ducts at about the 10th week, cytokeratin, particulary CK19, disappears from liver cells but remains in bile duct cells. This study shows that the immunoreactivity of the analyzed cytokeratins, in particular CK7 and CK19, is well evident from the first weeks of gestation and is maintained even in late age.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Hamou, Wissam. "Assessing liver regeneration by human embryonic stem cell-derived hepatocytes." Thesis, Paris 6, 2014. http://www.theses.fr/2014PA066374.

Повний текст джерела
Анотація:
Trouver de nouvelles sources de foie pour les transplantations est un vrai enjeu. Les obstacles principaux à la transplantation d'organes sont la pénurie de greffons et les lourds traitements immunosuppresseurs à vie. La possibilité de reprogrammer les cellules du patient et les cultiver donne accès à une quantité virtuellement illimitée de cellules a transplanter, éliminant de ce fait le besoin de donneurs d'organesMon doctorat se divise en deux parties : la première consiste à faire des cellules hépatiques en programmant des cellules souches humaines. La deuxième consiste à transplanter ces dernières dans des foies de souris ayant des insuffisances hépatiques aigues et chroniques pour étudier la régénération du foie. Les nouveautés de ce projet sont le fait d'étudier la première phase d'intégration post transplantation des cellules car cette phase est critique dans la régénération. De plus je comparerai la régénération du foie par les cellules transplantées dans une insuffisance hépatique aigue avec une insuffisance hépatique chronique. Une semaine après transplantation, le foie de ces souris contenait les cellules greffées qui se sont implantées et celles-ci se comportaient comme des cellules de foie bona fide, produisant une protéine, l'albumine humaine. Encore mieux : l'analyse des fonctions du foie a relevé un retour à une fonction normale en 3 jours avec transplantation contre 7 jours sans cellules transplantées. Ces résultats sont très encourageants quant à la possibilité d'utiliser des cellules dérivées de cellules souches à des fins thérapeutiques
Finding new sources for liver transplants is a real issue. The main obstacles to organ transplantation are the shortage of grafts and heavy immunosuppressive treatment for life. The ability to reprogram the patient's cells and grow them gives access to a virtually unlimited amount of transplanted cells, thereby eliminating the need for an organ donor. My doctorate is in two parts: the first is to make liver cells by programming of human stem cells. The second is to transplant those cells in the livers of mice with acute and chronic liver failure to study liver regeneration. The novel parts of this project are to study the first phase of post-integration cell transplantation because this phase is critical in regeneration. Also I would compare liver regeneration by transplanted cells in acute liver failure with chronic liver failure. One week after transplantation, the liver of these mice contained the grafted cells and which are located if they behaved as bona fide liver cells producing a protein, human albumin. Even better: analysis of liver function noted a return to normal function in three days with seven days without transplantation against transplanted cells. These results are very encouraging when the possibility of using cells derived from stem cells for therapeutic purposes
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Söderdahl, Therese. "Characterization of biotransformation systems in human cells : focus on stem cells and their progeny /." Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-206-4/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Liu, Chao. "Identification of liver stem-like cells in human derived intrahepatic biliary epithelial cells in vitro." [S.l.] : [s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=967345642.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Lindton, Bim. "Experimental studies of human fetal liver cells : in regard to in utero hematopoietic stem cell transplantation /." Stockholm, 2002. http://diss.kib.ki.se/2002/91-7349-134-9.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Minami, Takahito. "Novel hybrid three-dimensional artificial liver using human induced pluripotent stem cells and a rat decellularized liver scaffold." Kyoto University, 2020. http://hdl.handle.net/2433/253138.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Winkler, Sandra, Madlen Hempel, Sandra Brückner, Hans-Michael Tautenhahn, Roland Kaufmann, and Bruno Christ. "Identification of pathways in liver repair potentially targeted by secretory proteins from human mesenchymal stem cells." Universitätsbibliothek Leipzig, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-207430.

Повний текст джерела
Анотація:
Background: The beneficial impact of mesenchymal stem cells (MSC) on both acute and chronic liver diseases has been confirmed, although the molecular mechanisms behind it remain elusive. We aim to identify factors secreted by undifferentiated and hepatocytic differentiated MSC in vitro in order to delineate liver repair pathways potentially targeted by MSC. Methods: Secreted factors were determined by protein arrays and related pathways identified by biomathematical analyses. Results: MSC from adipose tissue and bone marrow expressed a similar pattern of surface markers. After hepatocytic differentiation, CD54 (intercellular adhesion molecule 1, ICAM-1) increased and CD166 (activated leukocyte cell adhesion molecule, ALCAM) decreased. MSC secreted different factors before and after differentiation. These comprised cytokines involved in innate immunity and growth factors regulating liver regeneration. Pathway analysis revealed cytokine-cytokine receptor interactions, chemokine signalling pathways, the complement and coagulation cascades as well as the Januskinase-signal transducers and activators of transcription (JAK-STAT) and nucleotide-binding oligomerization domain-like receptor (NOD-like receptor) signalling pathways as relevant networks. Relationships to transforming growth factor beta(TGF-beta) and hypoxia-inducible factor 1-alpha (HIF1-alpha) signalling seemed also relevant. Conclusion: MSC secreted proteins, which differed depending on cell source and degree of differentiation. The factors might address inflammatory and growth factor pathways as well as chemo-attraction and innate immunity. Since these are prone to dysregulation in most liver diseases, MSC release hepatotropic factors, potentially supporting liver regeneration.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Garg, Abhilok. "In vitro processing of human bone marrow derived mesenchymal stem cells to enhance delivery in liver disease." Thesis, University of Birmingham, 2013. http://etheses.bham.ac.uk//id/eprint/4326/.

Повний текст джерела
Анотація:
Currently the only effective treatment for end stage liver disease is transplantation together with immune-modulating drugs. Human bone marrow derived mesenchymal stem cells (MSC) have been shown to suppress inflammation, potentiate regeneration and act as vectors for gene therapy. Thus, MSC infusions offer an attractive potential therapy for treating liver disease. However a number of obstacles exist in MSC delivery before they can be used therapeutically. Although MSC can migrate to sites of injury after in vivo administration, their engraftment within the liver is often poor, potentially limiting their therapeutic action. I have shown that detaching MSC from culture using non-enzymatic methods is superior in retaining surface chemokine receptor expression. Furthermore, I have shown that these receptors are functional in migration and attachment assays both in vitro and in vivo in carbon-tetrachloride induced liver injury. TGFβ1 stimulated MSC were able to further enhance engraftment via up-regulation of surface CXCR3. Additionally the potent immunosuppressive properties of MSC, mediated via Prostaglandin E2, were enhanced after TGFβ1 stimulation. Thus my studies demonstrate that manipulation of MSC through careful choice of detachment methods and exogenous cytokine stimulation can improve their engraftment in injured liver and their immunosuppressive properties with implications for improving the efficacy of MSC therapy.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Human Liver Stem Cells"

1

I, Grishchenko V., та Instytut problem kriobiolohiï i kriomedyt͡s︡yny (Akademii͡a︡ nauk Ukraïnsʹkoï RSR), ред. Gemopoėticheskie kletki ėmbrionalʹnoĭ pecheni: Ėmbriogenez, transplantat͡s︡ii͡a︡ i kriokonservirovanie. Kiev: Nauk. dumka, 1988.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Ochiya, Takahiro, ed. Liver Stem Cells. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-61779-468-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Sell, Stewart. Liver stem cells. Austin: Landes Bioscience, 1997.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Liver stem cells: Methods and protocols. New York: Humana Press, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

ussinger, D. Ha. Liver regeneration. Berlin: de Gruyter, 2011.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Chiu, Arlene, and Mahendra S. Rao. Human Embryonic Stem Cells. New Jersey: Humana Press, 2003. http://dx.doi.org/10.1385/1592594239.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Lakshmipathy, Uma, Chad C. MacArthur, Mahalakshmi Sridharan, and Rene H. Quintanilla. Human Pluripotent Stem Cells. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781119394372.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Sullivan, Stephen, Chad A. Cowan, and Kevin Eggan, eds. Human Embryonic Stem Cells. Chichester, UK: John Wiley & Sons, Ltd, 2007. http://dx.doi.org/10.1002/9780470511619.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Schwartz, Philip H., and Robin L. Wesselschmidt, eds. Human Pluripotent Stem Cells. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-201-4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Masters, John R., and Bernhard Ø. Palsson, eds. Human Adult Stem Cells. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2269-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Human Liver Stem Cells"

1

Marongiu, Fabio, Maria Paola Serra, Marcella Sini, Ezio Laconi, Marc C. Hansel, Kristen J. Skvorak, Roberto Gramignoli, and Stephen C. Strom. "Advances and Possible Applications of Human Amnion for the Management of Liver Disease." In Perinatal Stem Cells, 197–208. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2013. http://dx.doi.org/10.1002/9781118497883.ch13.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Fanni, Daniela, Clara Gerosa, Federica Lai, and Gavino Faa. "Human Hepatic Stem/Progenitor Cells in Cancer and Liver Disease." In Stem Cells in Clinical Applications, 71–83. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-98065-2_5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Aoi, Takashi. "The Way to Clinical Application of Human Pluripotent Stem Cells." In Gene Therapy and Cell Therapy Through the Liver, 95–103. Tokyo: Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-55666-4_9.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Larijani, Bagher, Hamid-Reza Aghayan, Parisa Goodarzi, and Babak Arjmand. "GMP-Grade Human Fetal Liver-Derived Mesenchymal Stem Cells for Clinical Transplantation." In Methods in Molecular Biology, 123–36. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/7651_2014_101.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Tian, Lipeng, Neha Prasad, and Yoon-Young Jang. "In Vitro Modeling of Alcohol-Induced Liver Injury Using Human-Induced Pluripotent Stem Cells." In Methods in Molecular Biology, 271–83. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/7651_2014_168.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Riordon, Daniel R., and Kenneth R. Boheler. "Immunophenotyping of Live Human Pluripotent Stem Cells by Flow Cytometry." In Methods in Molecular Biology, 127–49. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7553-2_9.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Wakao, Shohei, Masaaki Kitada, Yasumasa Kuroda, and Mari Dezawa. "Isolation of Adult Human Pluripotent Stem Cells from Mesenchymal Cell Populations and Their Application to Liver Damages." In Methods in Molecular Biology, 89–102. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-61779-468-1_8.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Mouiseddine, Moubarak, Sabine François, Maâmar Souidi, and Alain Chapel. "Intravenous Human Mesenchymal Stem Cells Transplantation in NOD/SCID Mice Preserve Liver Integrity of Irradiation Damage." In Methods in Molecular Biology, 179–88. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-61779-468-1_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Pettinato, Giuseppe, Lev T. Perelman, and Robert A. Fisher. "Development of a Scalable Three-Dimensional Culture of Human Induced Pluripotent Stem Cells-Derived Liver Organoids." In Methods in Molecular Biology, 131–47. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2128-8_12.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Tateno, Hiroaki, Yasuko Onuma, and Yuzuru Ito. "Live-Cell Imaging of Human Pluripotent Stem Cells by a Novel Lectin Probe rBC2LCN." In Methods in Molecular Biology, 313–18. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1292-6_26.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Human Liver Stem Cells"

1

Wang, Xiao Qi, Chung Mau Lo, Lin Chen, Cindy KY Cheung, and Sheung Tat Fan. "Abstract 3299: Hematopoietic chimerism in liver transplantation patients and hematopoietic stem/progenitor cells in adult human liver." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3299.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Yamashita, Taro, Masao Honda, Kouki Nio, Yasumasa Hara, Takehiro Hayashi, Naoki Oishi, Hajime Sunakozaka, Hajime Takatori, and Shuichi Kaneko. "Abstract 262: The evolution of diverse cancer stem cells in human liver cancer." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-262.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Chusilp, Sinobol, Carol Lee, Bo Li, Dorothy Lee, Masaya Yamoto, Paisarn Vejchapipat, and Agostino Pierro. "The Fibrogenic Injury of Liver Ductal Organoids Is Rescued By Human Amniotic Fluid Stem Cells." In AAP National Conference & Exhibition Meeting Abstracts. American Academy of Pediatrics, 2021. http://dx.doi.org/10.1542/peds.147.3_meetingabstract.921-a.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Yamashita, Taro, Masao Honda, Kazunori Kawaguchi, Hajime Takatori, Hajime Sunakozaka, Xin W. Wang, and Shuichi Kaneko. "Abstract 5336: Distinct liver cancer stem cells defined by EpCAM and CD90 in human hepatocellular carcinoma." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5336.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Ingerslev, J., B. Sloth Christiansen, A. Bukh, S. Stenbjerg, T. Munck Jørgensen, and C. Munck Petersen. "HUMAN HEPATOCYTES CONTAIN HIGH MOLECULAR WEIGHT POLYPEPTIDES OF FACTOR VIII." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644324.

Повний текст джерела
Анотація:
Human hepatocytes were isolated by the two-step collagenase technique applied on distal left liver lobe. Homogenous and large cells were isolated revealing hepatocyte characteristics by light-microscopy. Hepatocytes were washed repeatedly in albumine buffer (5%), resuspended in the same buffer and sonicated using a cell density of 0.75 × 106 cells/ml. In some cases cells were separated from non-viable cells by flotation on a linear Percoll gradient. Supernate material after sonication was subjected to ELISA for VIII:Ag using human antibodies and vWf:Ag by polyclonal antibodies. Freshly isolated cells contained at least 0.25 IU/ 0.75 × 106 hepatocytes, whereas the vWf:Ag was below 0.01 IU/ 0.75 × 106 cells. The material obtained from sonication was further studied using fast protein liquid chromatography by Mono-Q HR 5/5 revealing a single peak of VIII: Ag eluting in the same position as the high molecular weight polypeptides of VIII :Ag of high purity FVIII derived from the plasma source. Isolated hepatocytes also were cultivated at 37°C in medium RPMI 1640 supplemented with Ultroser G (4%), glutamine and antibiotics. Cells secreted increasing quantities of albumin, fitrinogpn and protease-inhibitors. The supernatants also contained VIII: Ag in quantities ranging from 0.04 - 0.17 IU/ml after 24 hours, but no further secretion was observed. No vWf: Ag could be detected. Cells harvested and sonicated after 30 hours of culture only contained 0.04 IU/ 0.75 × 106 cells. Our results shows, that VIII :Ag is present in freshly isolated human hepatocytes and that only traces of vWf:Ag is found. A hepatocyte site of production of VIII is speculated. These very preliminary findings do not permit conclusions concerning active synthesis of VIII in hepatocytes. Further studies are underway.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Achyuthan, K. E., M. J. Borowitz, M. A. Shuman, and C. S. Greenberg. "THROMBIN INDEPENDENT TRANSGLUTAMINASE IN VASCULAR CELLS AND TISSUES MAY PROVIDE AN ALTERNATE PATHWAY TOWARD CLOT STABILIZATION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643775.

Повний текст джерела
Анотація:
Blood coagulation Factor XIIla (FXIIIa) is a thrombin activated transglutaminase (TG) that is involved in the final step of fibrin stabilization. FXIIIa inhibits fibrinolysis by crosslinking α-2-plasmin inhibitor (α-2-PI) to fibrin. A thrombin-independent TG has been identified in vascular cells and tissues -from human, rabbit, rat, porcine and bovine sources. The vascular TG had several properties similar to the well characterized guinea pig liver TG. Both enzymes had similar molecular weights (80-90 kDa) and similar chromatographic and electrophoretic properties. Both enzymes preferentially crosslinked α-chains of fibrinogen and their TG activities were independent of thrombin treatment. Finally, both enzymes reacted with polyclonal and monoclonal antibodies to guinea pig liver TG. However, the TG from cultured adult bovine aortic endothelial (ABAE) cells exhibited a novel Ca++/Mg++ dependence for enzymatic activity which was distinct from purified liver TG. TG from confluent ABAE cells and rabbit vascular smooth muscle cells had between 4-7 fold higher TG activity compared to rapidly dividing (nonconfluent) cells -from the same passage. The difference in activity was not due to enhanced degradation of TG catalyzed isopeptide bonds by nonconfluent cells Upon examination by immunoblots using anti-TG antibodies, the TG antigen in nonconfluent cells appeared extensively degraded. Furthermore, guanosine-5'-triphosphate (GTP) was nearly 3-fold more inhibitory to TG from confluent cells compared to nonconfluent cells. Proteases, GTP and divalent cation levels may be modulating intracellular TG activity. The TG antigen detected by imm-unohistochemical techniques was predominantly associated with endothelial and smooth muscle cells of arteries, veins, venules and capillaries. TG antigen also codistributed with fibronectin antigen along the hepatic sinusoids. The ABAE cell TG crosslinked α-2-PI to fibrinogen. The modified fibrinogen was 40-fold more resistant to plasminolysis compared to unmodified fibrinogen. In conclusion, the presence of a thrombin-independent TG in blood vessels may provide an alternate pathway to inhibit fibrinolysis and promote clot stabilization.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Lee, Jae W., Anna Krasnodembskaya, Xiaohui Fang, David H. McKenna, E. J. Read, and Michael A. Matthay. "Allogeneic Human Mesenchymal Stem Cells Inhibit Bacterial Growth And Restore Normal Alveolar Fluid Transport In An Ex Vivo Perfused Human Lung Injured By Live E. Coli." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1247.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Tourlomousis, Filippos, and Robert C. Chang. "Computational Modeling of 3D Printed Tissue-on-a-Chip Microfluidic Devices as Drug Screening Platforms." In ASME 2014 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/imece2014-38454.

Повний текст джерела
Анотація:
Physiological tissue-on-a-chip technology is enabled by adapting microfluidics to create micro scale drug screening platforms that replicate the complex drug transport and reaction processes in the human liver. The ability to incorporate three-dimensional (3d) tissue models using layered fabrication approaches into devices that can be perfused with drugs offer an optimal analog of the in vivo scenario. The dynamic nature of such in vitro metabolism models demands reliable numerical tools to determine the optimum tissue fabrication process, flow, material, and geometric parameters for the most effective metabolic conversion of the perfused drug into the liver microenvironment. Thus, in this modeling-based study, the authors focus on modeling of in vitro 3d microfluidic microanalytical microorgan devices (3MD), where the human liver analog is replicated by 3d cell encapsulated alginate hydrogel based tissue-engineered constructs. These biopolymer constructs are hosted in the chamber of the 3MD device serving as walls of the microfluidic array of channels through which a fluorescent drug substrate is perfused into the microfluidic printed channel walls at a specified volumetric flow rate assuring Stokes flow conditions (Re<<1). Due to the porous nature of the hydrogel walls, a metabolized drug product is collected as an effluent stream at the outlet port. A rigorous modeling approached aimed to capture both the macro and micro scale transport phenomena is presented. Initially, the Stokes Flow Equations (free flow regime) are solved in combination with the Brinkman Equations (porous flow regime) for the laminar velocity profile and wall shear stresses in the whole shear mediated flow regime. These equations are then coupled with the Convection-Diffusion Equation to yield the drug concentration profile by incorporating a reaction term described by the Michael-Menten Kinetics model. This effectively yields a convection-diffusion–cell kinetics model (steady state and transient), where for the prescribed process and material parameters, the drug concentration profile throughout the flow channels can be predicted. A key consideration that is addressed in this paper is the effect of cell mechanotransduction, where shear stresses imposed on the encapsulated cells alter the functional ability of the liver cell enzymes to metabolize the drug. Different cases are presented, where cells are incorporated into the geometric model either as voids that experience wall shear stress (WSS) around their membrane boundaries or as solid materials, with linear elastic properties. As a last step, transient simulations are implemented showing that there exists a tradeoff with respect the drug metabolized effluent product between the shear stresses required and the residence time needed for drug diffusion.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Chen, Jian, Jiun-Sheng Chen, Zhixing Yao, Wilma Jogunoori, Bibhuti Mishra та Lopa Mishra. "Abstract 115: Telomerase modulation in a human cancer stem cell syndrome with loss of TGF-β signaling is a promising treatment strategy in liver and gastrointestinal cancers". У Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-115.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Chen, Hsiuhung, Zhiquan Shu, and Dayong Gao. "Development of a Controlled Rate Cooling System for Cryopreservation." In ASME 2008 3rd Frontiers in Biomedical Devices Conference. ASMEDC, 2008. http://dx.doi.org/10.1115/biomed2008-38062.

Повний текст джерела
Анотація:
Cooling rate is one of the most critical factors affecting the survival of cells during cryopreservation. A novel box-in-box device has been developed for use in the cryopreservation of human hematopoietic stem cells (HSCs). This work presents the comparison of experimentally observed thermal profiles for two different setups and, in the near future, cryopreservation survival rates of live cells accordingly. In experiments, using a simple protocol with a −80°C freezer, the box-in-box device is used to: (1) achieve an average cooling rate of −1°C/min with polyethylene insulation layers on both sides, and (2) achieve an average cooling rate of −2°C/min with a polyethylene insulation layer on one side and by having the other side directly contacted to the outermost aluminum case, both from room temperature to −40°C. The concept that utilizes thermal inertia of materials may be readily adapted to other cooling rates to support cryopreservation of a wide array of tissues and cells. It is concluded that the box-in-box system can be developed into a cost-effective, durable and reliable device for the cryopreservation of HCSs.
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Human Liver Stem Cells"

1

Eirew, Peter D. Characterization of Human Mammary Epithelial Stem Cells. Fort Belvoir, VA: Defense Technical Information Center, October 2008. http://dx.doi.org/10.21236/ada501896.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Eirew, Peter D. Characterization of Human Mammary Epithelial Stem Cells. Fort Belvoir, VA: Defense Technical Information Center, October 2007. http://dx.doi.org/10.21236/ada516902.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Hsu, E. W. Imaging of Human Hepatic Stem Cells In Vivo. Office of Scientific and Technical Information (OSTI), March 2006. http://dx.doi.org/10.2172/877135.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Ying, Mingyao. Modeling Aggressive Medulloblastoma Using Human-Induced Pluripotent Stem Cells. Fort Belvoir, VA: Defense Technical Information Center, July 2015. http://dx.doi.org/10.21236/ada620932.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Palappattu, Ganesh. The Isolation and Characterization of Human Prostate Cancer Stem Cells. Fort Belvoir, VA: Defense Technical Information Center, February 2011. http://dx.doi.org/10.21236/ada542728.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Palapattu, Ganesh S. The Isolation and Characterization of Human Prostate Cancer Stem Cells. Fort Belvoir, VA: Defense Technical Information Center, August 2009. http://dx.doi.org/10.21236/ada518099.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Palapattu, Ganesh S. The Isolation and Characterization of Human Prostate Cancer Stem Cells. Fort Belvoir, VA: Defense Technical Information Center, February 2014. http://dx.doi.org/10.21236/ada601047.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Palapattu, Ganesh S. The Isolation and Characterization of Human Prostate Cancer Stem Cells. Fort Belvoir, VA: Defense Technical Information Center, February 2013. http://dx.doi.org/10.21236/ada604404.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Palapattu, Ganesh. The Isolation and Characterization of Human Prostate Cancer Stem Cells. Fort Belvoir, VA: Defense Technical Information Center, February 2012. http://dx.doi.org/10.21236/ada560654.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Hristova, Marina, Plamen Todorov, Nadya Petrova, Diana Gulenova, Ibryam Ibryam, and Elena Hristova. Clonogenic Activity of Human Haematopoietic Stem Cells Cultured under Micro-vibrations. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, May 2018. http://dx.doi.org/10.7546/crabs.2018.04.08.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Human Liver Stem Cells" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії